BioAtla (BCAB) EBIT (2020 - 2026)
BioAtla (BCAB) posted quarterly EBIT of -$9.3 million for Q1 2026, up 47.16% year-over-year from -$6.3 million in Q1 2025, and down 0.57% quarter-over-quarter from -$9.3 million in Q4 2025.
BioAtla (BCAB) EBIT (2020 - 2026) Analysis & Trends
BioAtla's EBIT history runs 7 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, EBIT rose 47.16% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$51.0 million (up 24.0% YoY), while the FY2025 annual figure was -$59.3 million, up 19.8% from the prior year.
- EBIT for Q1 2026 stood at -$9.3 million, down from -$9.3 million in the prior quarter.
- The five-year high for EBIT was -$9.3 million in Q4 2025, with the low at -$37.2 million in Q2 2023.
- The 5-year median for EBIT is -$24.3 million (2022), against an average of -$22.4 million.
- The sharpest annual moves came in 2023 and 2024: EBIT plunged 33.77% in 2023, then soared 67.82% in 2024.
- BioAtla's EBIT stood at -$28.6 million in 2022, then increased by 0.08% to -$28.5 million in 2023, then surged by 43.08% to -$16.2 million in 2024, then jumped by 43.03% to -$9.3 million in 2025, then retreated by 0.57% to -$9.3 million in 2026.
- Business Quant data shows BCAB's EBIT at -$9.3 million in Q1 2026, -$9.3 million in Q4 2025, and -$13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 227,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 227,000.00 |
| Mar 31, 2026 | -9.31 Mn |
| Dec 31, 2025 | -9.26 Mn |
| Sep 30, 2025 | -13.79 Mn |
| Jun 30, 2025 | -18.65 Mn |
| Mar 31, 2025 | -17.61 Mn |
| Dec 31, 2024 | -16.24 Mn |
| Sep 30, 2024 | -11.27 Mn |
| Jun 30, 2024 | -21.97 Mn |
| Mar 31, 2024 | -24.46 Mn |
| Dec 31, 2023 | -28.54 Mn |
| Sep 30, 2023 | -35.02 Mn |
| Jun 30, 2023 | -37.20 Mn |
| Mar 31, 2023 | -28.93 Mn |
| Dec 31, 2022 | -28.56 Mn |
| Sep 30, 2022 | -26.18 Mn |
| Jun 30, 2022 | -29.06 Mn |
| Mar 31, 2022 | -24.35 Mn |
| Dec 31, 2021 | -23.49 Mn |
| Sep 30, 2021 | -23.70 Mn |